A Prognostic Nomogram Based on Immune Scores Predicts Postoperative Survival for Patients with Hepatocellular Carcinoma

Table 3

Multivariate analyses of the OS and DFS of hepatocellular carcinoma patients according to clinical characteristics and immune scores.

Characteristics	OS		DFS
	HR (95% CI)		HR (95% CI)
Age (years)
≤30	1.000		1.000
31-40	2.733 (0.299, 25.008)	0.373	0.549 (0.215, 1.403)	0.210
41-50	3.054 (0.373, 25.009)	0.298	0.397 (0.170, 0.930)	0.033
51-60	3.338 (0.440, 25.321)	0.244	0.507 (0.240, 1.067)	0.074
61-70	2.427 (0.317, 18.607)	0.394	0.456 (0.218, 0.952)	0.037
71-80	4.465 (0.577, 34.578)	0.152	0.582 (0.262, 1.291)	0.183
>80	5.027 (0.290, 87.030)	0.267	0.393 (0.080, 1.927)	0.249
Stage
I	1.000		1.000
II	1.332 (0.641, 2.768)	0.443	2.078 (1.396, 3.095)	<0.001
III	4.218 (2.397, 7.421)	<0.001	2.717 (1.854, 3.981)	<0.001
IV	13.552 (2.939, 62.485)	0.001	7.634 (2.246, 25.951)	0.001
Immune score
Low	1.000		1.000
Medium	0.417 (0.186, 0.937)	0.034	0.575 (0.329, 1.004)	0.052
High	0.299 (0.146, 0.616)	0.001	0.451 (0.278, 0.733)	0.001